Renal Failure News and Research

RSS

Renal failure or kidney failure is where the kidneys fail to function adequately. Renal failure is divided in acute and chronic forms; either form may be due to a large number of other medical problems.

Early use of norepinephrine could benefit patients with sepsis and low blood pressure

Patients with septic shock who were treated with norepinephrine earlier than patients receiving standard care were more likely to have their blood pressure and shock stabilized within six hours of diagnosis, according to a randomized, double-blind, controlled trial published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.

4 Feb 2019

Excessive suppression of GSK3 enzyme can trigger renal failure, finds study

Scientists have identified an enzyme that is a "master regulator" of kidney function that if excessively suppressed, can trigger renal failure. Their findings have implications for the use of existing drugs and the development of new pharmaceuticals.

24 Jan 2019

Elevated hormone flags liver disease in mice with serious genomic disorder

Researchers have discovered that a hormone, fibroblast growth factor 21 (FGF21), is extremely elevated in mice with liver disease that mimics the same condition in patients with methylmalonic acidemia (MMA), a serious genomic disorder.

6 Dec 2018

New ointment for treating brown recluse spider bites is tested on humans

The bite from a brown recluse spider (Loxosceles) can cause skin necrosis, renal failure, and even death. A new ointment is being tested in Brazil, however. Its effects have already been proven in tests conducted in cell cultures and animal models.

29 Nov 2018

Diabetes medication reduces risk of heart failure hospitalization

In the largest trial to date to assess cardiovascular outcomes for an important class of diabetes medications, researchers have found that dapagliflozin markedly reduced the risk of hospitalization for heart failure in a broad population of patients with diabetes.

12 Nov 2018

4TECH successfully completes first two implantations of TriCinch Coil tricuspid valve repair system

4TECH Inc., a leader in the field of transcatheter tricuspid valve repair, initiated its U.S. Early Feasibility Study, following receipt of approval from the U.S. Food and Drug Administration, with the successful first two implantations of the TriCinch Coil System at Piedmont Heart Hospital, Atlanta, Georgia, by Dr. Christopher Meduri, Dr. Vivek Rajagopal and Dr. Mani Vannan.

1 Nov 2018

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

New urea sorbent could speed up the development of wearable artificial kidney

There just aren't enough kidney transplants available for the millions of people with renal failure.

19 Oct 2018

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.

17 Oct 2018

Length of hospital stay and readmission likelihood increases by 2.9% in rural areas, review finds

Hospital readmissions cost hospitals about $26 billion annually. Systems like the Hospital Readmission Reduction Program within the Affordable Care Act penalize hospitals with higher readmission rates for targeted diagnoses.

5 Oct 2018

Mesoblast’s MPC therapy for children featured at symposium for congenital heart disease

Mesoblast Limited today announced that Mesoblast's proprietary allogeneic mesenchymal precursor cell heart failure product candidate MPC-150-IM for use in children with hypoplastic left heart syndrome was featured at the First Cardiac Regenerative Symposium for Congenital Heart Disease in Baltimore, Maryland on the weekend.

26 Sep 2018

Study reveals promising new drug candidate to treat acute renal failure

A protein produced by the human body appears to be a promising new drug candidate to treat conditions that lead to acute renal failure. This is shown by a study conducted at São Paulo State University in São José do Rio Preto, Brazil.

20 Sep 2018

Sesen Bio to present its three-month Phase 3 VISTA Trial data at Global Congress

Sesen Bio, Inc., a late-stage clinical company developing fusion protein therapies for the treatment of cancer, today announced that the company will present its three-month Phase 3 VISTA Trial data during a poster session at the Global Congress on Bladder Cancer 2018.

20 Sep 2018

Previously unknown virus acts as 'driver' for interstitial nephropathy

An international research team led by Wolfgang Weninger, who has been Head of MedUni Vienna's Department of Dermatology since 1 September, has discovered a previously unknown virus that acts as a "driver" for certain kidney diseases (interstitial nephropathy).

14 Sep 2018

FDA approves new treatment for people with hairy cell leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

FDA approves first therapy for patients with rare tumors of the adrenal gland

The U.S. Food and Drug Administration today approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or paraganglioma) that cannot be surgically removed (unresectable), have spread beyond the original tumor site and require systemic anticancer therapy.

31 Jul 2018

Aggressive lowering of blood pressure reduces MCI risk, study shows

Significant reductions in the risk of mild cognitive impairment (MCI), and the combination of MCI and dementia, have been shown for the first time through aggressive lowering of systolic blood pressure in new research results from the federally-funded SPRINT MIND Study reported at the Alzheimer's Association International Conference 2018 in Chicago.

25 Jul 2018

Renal Failure News and Research

Further Reading